Shanghai Fosun Pharmaceutical (600196.SH): The registration application for the drug Engliglitazone and Metformin slow-release tablets has been accepted.
Fosun Pharma (600196.SH) announces that its holding subsidiary, Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd. has...
Shanghai Fosun Pharmaceutical (600196.SH) announced that its holding subsidiary, Jiangsu Wanbang Biochemical Pharmaceutical Group Co., Ltd., has recently had its drug registration application for the sustained-release tablet of Englitazone and Metformin Hydrochloride accepted by the National Medical Products Administration. The drug is intended for the treatment of type 2 diabetes.
Related Articles
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Wondershare Technology Group (300624.SZ) has upgraded its Wondershare Filmora desktop version: free video editing, better AI results!
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
